Evidence map›Paper›PMID 37103297›Full record

ArticleJournal of functional biomaterials2023

Hypochlorous Acid-Activated UCNPs-LMB/VQIVYK Multifunctional Nanosystem for Alzheimer's Disease Treatment.

Luying Qiao, Yang Shen, Guangzhi Li, Guanglei Lv, Chunxia Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of functional biomaterials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luying QiaoInstitute of Molecular Sciences and Engineering, Institute of Frontier and Interdisciplinarity Science, Shandong University, Qingdao 266237, China.
Yang ShenCenter for Biotechnology and Biomedical Engineering, Yiwu Research Institute of Fudan University, Yiwu 322000, China.
Guangzhi LiCollege of Pharmacy, Jiamusi University, Jiamusi 154007, China.
Guanglei LvCenter for Biotechnology and Biomedical Engineering, Yiwu Research Institute of Fudan University, Yiwu 322000, China.
Chunxia LiInstitute of Molecular Sciences and Engineering, Institute of Frontier and Interdisciplinarity Science, Shandong University, Qingdao 266237, China.

Funding

National Natural Science Foundation of China 51872263, 52272156 and 52250077
6 · The paper itself

Abstract

The development of nanosystems, which can photooxygenate amyloid-β (Aβ), detect the Tau protein, and inhibit effectively the Tau aggregation, is increasingly important in the diagnosis and therapy of Alzheimer's disease (AD). Herein, UCNPs-LMB/VQIVYK (UCNPs: upconversion nanoparticles, LMB: Leucomethylene blue, and VQIVYK: Biocompatible peptide) is designed as a HOCl-controlled released nanosystem for AD synergistic treatment. Under exposure to high levels of HOCl, the released MB from UCNPs-LMB/VQIVYK will produce singlet oxygen (

Indexed as

Alzheimer’s diseaseamyloid-βreactive oxygen speciesTau proteinupconversion

Identifiers

PMID37103297
PMCPMC10143957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.